Log in

NASDAQ:EARSAuris Medical Stock Price, Forecast & News

$1.03
+0.01 (+0.98 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.98
Now: $1.03
$1.04
50-Day Range
$0.78
MA: $0.94
$1.10
52-Week Range
$0.65
Now: $1.03
$3.20
Volume146,197 shs
Average Volume370,296 shs
Market Capitalization$4.75 million
P/E RatioN/A
Dividend YieldN/A
Beta0.17
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.
Read More
Auris Medical logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EARS
CUSIPN/A
Phone441-295-5950

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.47 per share

Profitability

Miscellaneous

Employees9
Market Cap$4.75 million
Next Earnings Date7/16/2020 (Estimated)
OptionableNot Optionable

Receive EARS News and Ratings via Email

Sign-up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.

Auris Medical (NASDAQ:EARS) Frequently Asked Questions

How has Auris Medical's stock been impacted by COVID-19 (Coronavirus)?

Auris Medical's stock was trading at $0.8829 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EARS stock has increased by 16.7% and is now trading at $1.03. View which stocks have been most impacted by Coronavirus.

When is Auris Medical's next earnings date?

Auris Medical is scheduled to release its next quarterly earnings announcement on Thursday, July 16th 2020. View our earnings forecast for Auris Medical.

How were Auris Medical's earnings last quarter?

Auris Medical Holding Ltd (NASDAQ:EARS) released its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.80) by $1.60. View Auris Medical's earnings history.

When did Auris Medical's stock split? How did Auris Medical's stock split work?

Shares of Auris Medical reverse split on the morning of Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.

Has Auris Medical been receiving favorable news coverage?

Press coverage about EARS stock has trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Auris Medical earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the near future. View the latest news aboutAuris Medical.

Who are some of Auris Medical's key competitors?

What other stocks do shareholders of Auris Medical own?

Who are Auris Medical's key executives?

Auris Medical's management team includes the following people:
  • Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)
  • Mr. Hernan Levett C.P.A., CPA, Chief Financial Officer (Age 43)
  • Colleen A. DeVries, SVP of Cogency Global Inc.

What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

Who are Auris Medical's major shareholders?

Auris Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (1.94%).

Which major investors are selling Auris Medical stock?

EARS stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC.

How do I buy shares of Auris Medical?

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Auris Medical's stock price today?

One share of EARS stock can currently be purchased for approximately $1.03.

How big of a company is Auris Medical?

Auris Medical has a market capitalization of $4.75 million. The biotechnology company earns $-6,680,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Auris Medical employs 9 workers across the globe.

What is Auris Medical's official website?

The official website for Auris Medical is www.aurismedical.com.

How can I contact Auris Medical?

Auris Medical's mailing address is Clarendon House 2 Church Street, Hamilton D0, HM 11. The biotechnology company can be reached via phone at 441-295-5950 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.